Want to create an interactive transcript for this episode?
Podcast: PeerView Heart, Lung & Blood CME/CNE/CPE Audio Podcast
Episode: Marina Chiara Garassino, MD - Are You Prepared for the New Wave of ADCs in NSCLC? Innovative Approaches and Practical Considerations in Targeting HER2, HER3, TROP2, and Other Alterations in Advanced Lung Cancer
Description: Go online to PeerView.com/FVE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Mounting evidence continues to support the clinical potential of antibody–drug conjugates (ADCs) in the treatment of patients with lung cancer, bringing hope to patients with limited treatment options. For example, novel HER2-targeting ADCs have demonstrated remarkable efficacy in advanced NSCLC, particularly in patients with HER2 mutations. ADCs targeting HER3, TROP2, and other alterations (eg, CEACAM5 and MET) are also producing promising data. In the context of these advances, it is important to learn to identify the ri...